| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 113.50 | 1007 |
| Intrinsic value (DCF) | 0.10 | -99 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 3.50 | -66 |
CRISM Therapeutics Corporation (CRTX.L) is a biotechnology company specializing in innovative drug delivery technologies aimed at enhancing the clinical efficacy of cancer treatments for solid tumors. Headquartered in the British Virgin Islands and listed on the London Stock Exchange, CRISM focuses on its proprietary ChemoSeed technology—a localized drug delivery system designed to be implanted directly into tumors or resection margins post-surgery. This approach ensures targeted, high-concentration chemotherapy delivery, minimizing systemic side effects. The company’s lead application targets gliomas, a challenging form of brain tumor, positioning CRISM in the high-need oncology segment. Founded in 2016, CRISM operates in the competitive biotechnology sector, where advancements in precision medicine and targeted therapies are driving growth. With no current revenue and a focus on R&D, CRISM represents a high-risk, high-reward opportunity for investors interested in cutting-edge cancer therapeutics.
CRISM Therapeutics presents a speculative investment opportunity with significant potential in the oncology drug delivery space. The company’s ChemoSeed technology offers a differentiated approach to localized chemotherapy, addressing unmet needs in solid tumor treatment. However, with no revenue, negative net income (£9.6 million loss in FY 2023), and reliance on clinical development milestones, CRISM carries substantial risk. The company’s £4.4 million cash position provides limited runway, necessitating future financing. A low beta (0.225) suggests limited correlation to broader market movements, but the stock is highly sensitive to clinical progress. Investors should weigh the innovative technology against the long development timelines and regulatory hurdles inherent in biotech.
CRISM Therapeutics competes in the niche but growing field of localized drug delivery systems for oncology. Its ChemoSeed technology differentiates by enabling sustained, high-dose chemotherapy directly at the tumor site, potentially improving efficacy while reducing systemic toxicity—a key advantage over conventional IV chemotherapy. However, CRISM faces intense competition from established oncology-focused biotech and pharma companies with broader pipelines and greater resources. The company’s focus on gliomas is strategic, given the lack of effective treatments, but it also competes with other targeted therapies (e.g., immunotherapies, radiation enhancers). CRISM’s early-stage status and lack of commercialization experience are weaknesses compared to larger peers. Success hinges on clinical validation, IP protection, and scalability of its delivery platform. The company’s asset-light model (no debt, minimal capex) is a strength, but reliance on partnerships for development and distribution could dilute upside.